SCHEMBL4449587

SCHEMBL4449587

COc1ccc(C(=O)C=Cc2ccc(OC)c(OC)c2OC)c(O)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.77
MEN1 O00255 2/20 0.77
MAPK1 P28482 2/20 0.77
KMT2A Q03164 2/20 0.77
NPC1 O15118 2/20 0.77
RAB9A P51151 2/20 0.77
APP P05067 3/20 0.71
CHRNA7 P36544 2/20 0.70
ABCG2 Q9UNQ0 5/20 0.66
FLT3 P36888 1/20 0.66
LMNA P02545 2/20 0.62
CYP3A4 P08684 1/20 0.62
CYP2C19 P33261 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
CTSL P07711 1/20 0.62
ALOX5 P09917 1/20 0.61
PDE4A P27815 1/20 0.61
PDE4B Q07343 1/20 0.61
PDE4C Q08493 1/20 0.61
PDE4D Q08499 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4449583 1.00 MAPT (0.77) MAPTMEN1MAPK1KMT2ANPC1
SCHEMBL30912311 0.90 MAPT (0.69) MAPTMEN1MAPK1KMT2ANPC1
SCHEMBL29225565 0.90 MAPT (0.69) MAPTMEN1MAPK1KMT2ANPC1
SCHEMBL29225566 0.90 MAPT (0.69) MAPTMEN1MAPK1KMT2ANPC1
SCHEMBL30138822 0.90 MAPT (0.78) MAPTMEN1MAPK1KMT2ANPC1
SCHEMBL5138233 0.89 MAPT (0.71) MAPTMEN1MAPK1KMT2ANPC1
SCHEMBL5138238 0.89 MAPT (0.71) MAPTMEN1MAPK1KMT2ANPC1
SCHEMBL634357 0.87 MAPT (1.00) MAPTMEN1MAPK1KMT2ANPC1
SCHEMBL634358 0.87 MAPT (1.00) MAPTMEN1MAPK1KMT2ANPC1
SCHEMBL5084271 0.87 APP (0.82) MAPTMEN1MAPK1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090182058-A1 Novel Chalcone Derivatives With Antimitotic Activity UNIVERSITE JOSEPH FOURIER GRENOBLE I (FR) 2009-07-16 US claimed
US-20090182058-A1 Novel Chalcone Derivatives With Antimitotic Activity UNIVERSITE JOSEPH FOURIER GRENOBLE I (FR) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090182058-A1 Novel Chalcone Derivatives With Antimitotic Activity ABCE1, CCNE1, FOXM1 MAPT 4453/4885MEN1 2708/4885MAPK1 1125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.